BiotechTube
Claris Bio

Claris Bio

Cambridge, United States· Est.
clarisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $57M

Overview

Claris Bio is a private, pre-revenue biotechnology company developing a topical biologic therapy for corneal regeneration. The company's lead asset, CSB-001, is a dHGF molecule designed to restore structural and functional integrity in eyes with Limbal Stem Cell Deficiency (LSCD), a severe and sight-threatening condition with limited treatment options. Founded by scientific leaders from Massachusetts Eye and Ear and an experienced ophthalmology CEO, Claris leverages licensed IP from MEEI and a drug substance agreement with Kringle Pharma to advance its program. The company is led by a seasoned team with deep expertise in ophthalmic drug development, clinical strategy, and business development.

OphthalmologyCorneal Diseases

Technology Platform

Topical ocular biologic therapy based on desalted Hepatocyte Growth Factor (dHGF) for corneal regeneration and repair.

Funding History

1
Total raised:$57M
Venture$57M

Opportunities

A successful topical therapy for LSCD would address a complete unmet medical need with no approved drugs, positioning it as a potential standard of care.
Positive proof-of-concept data could unlock significant partnership or acquisition interest from larger ophthalmic companies.
The HGF platform biology offers potential for expansion into other large-market corneal conditions like persistent epithelial defects.

Risk Factors

High clinical development risk as promising preclinical data must be confirmed in human trials for a complex disease.
Significant financing risk as a private, pre-revenue company needing to fund costly clinical studies.
Competitive and regulatory risks associated with pioneering a novel biologic in a challenging therapeutic area.

Competitive Landscape

The direct competitive landscape for LSCD is primarily surgical (limbal transplants, keratoprosthesis). Pharmacologic competition is nascent but may include other growth factor-based approaches or cell therapies. Indirectly, Claris competes for funding and partnership attention within the broader ophthalmic innovation space.

More companies in Biologics / Biosimilars →More companies in United States →